Larvol Delta

long-acting sequence-modified recombinant factor VIIa (BAY 866150) - Bayer

New York Management Meet (Bayer) - Jun 12, 2012 - Anticipated initiation of P2/P3 study for hemophilia in 2012
Anticipated P2/3 trial initiation • Hemophilia

http://www.larvolonline.com/tlg/ccdb/BayerNewYorkManagementMeetJun12'12.pdf

Jun 12, 2012

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

BAY 866150 -- -- -- Recombinant FVIIa: target to initiate a phase II/III study in 2012 -- -- --